钇-90玻璃微球经动脉放射栓塞治疗肝细胞癌后动态肝胆对比增强MRI信号强度分析
本研究为单机构回顾性研究,分析58例肝细胞癌患者接受钇-90玻璃微球经动脉放射栓塞(TARE)后,靶肝段与未靶肝实质在动态肝胆对比增强MRI上的信号强度差异。结果显示肝胆期信号强度差异最显著,且在所有评估的剂量阈值下均存在;中位随访6个月。
要点
- TARE后肝胆期靶肝较未靶肝信号强度显著降低,差异为-95.8(p≤0.001)。
- 肝胆期信号强度改变在所有评估的TARE剂量阈值(<120 Gy、120-190 Gy、>190 Gy)均显著(p<0.05)。
- 非增强期和动脉期亦见显著信号强度差异,而门静脉期和移行期无显著差异。
关键影像表现/征象
- 靶肝与未靶肝信号强度差异在非增强期为-28.0(p=0.003),动脉期为38.5(p=0.013),肝胆期为-95.8(p≤0.001)。
- 门静脉期和移行期靶肝与未靶肝信号强度无显著差异。
- 肝胆期靶肝较未靶肝的信号强度改变在所有TARE剂量阈值(<120 Gy、120-190 Gy、>190 Gy)均显著(p<0.05)。
诊断标准与关键数值
- 中位TARE剂量为141.5 Gy MIRD(IQR 122.0-161.5;范围100-540 Gy)。
- 中位随访至最远治疗后MRI时间为6个月(范围3-11个月)。
临床应用与阅片要点
- 阅片时关注肝胆期靶肝段信号强度减低,其与未靶肝的差异最显著,可用于评估TARE后的肝实质改变。
- 门静脉期和移行期信号强度差异不显著,评估TARE后改变时肝胆期价值更大。
- 肝胆期信号强度改变在所有评估的剂量阈值下均存在,报告时需结合剂量信息。
局限性
- 本研究为单机构回顾性研究。
- 排除既往接受局部区域治疗或多次TARE的患者,可能限制结论的普适性。
- 中位随访至最远治疗后MRI时间仅6个月(范围3-11个月),随访时间较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To analyze hepatobiliary specific contrast agent (HBA) dynamic MRI signal intensity (SI) differences between treated liver (TL) and untreated liver (UL) parenchyma in patients following transarterial radioembolization (TARE) for hepatocellular carcinoma (HCC) using yttrium-90 containing glass microspheres.
MATERIALS: This was a single institution retrospective study of patients with HCC treated with lobar or segmental TARE who received pre- and post-treatment HBA multiphase MRI within a 3-year period. Patients with prior locoregional therapies or multiple TAREs were excluded. SI was obtained by drawing a 2D ROI on T1-weighted non-contrast, arterial (25 s.), portal venous (60 s.), transitional (180 s.), and hepatobiliary (HB) (1200 s.) phase sequences in the (TL) angiosome and UL. HB phase signal enhancement characteristics were correlated with TARE dose thresholds (< 120 Gy, 120-190 Gy, and > 190 Gy) using the medical internal radiation dose (MIRD) methodology.
RESULTS: 282 patients received TARE using glass microspheres during the study period and 58 patients who met inclusion criteria were analyzed. Median dose was 141.5 Gy MIRD [IQR 122.0, 161.5; range 100-540 Gy]). Statistically significant differences were present between treated and non-treated liver on non-contrast (- 28.0, p = 0.003), arterial (38.5, p = 0.013), and HB phases (- 95.8, p ≤ 0.001). Median follow-up time to furthest post-treatment MRI was 6 months (range 3-11 months). There was no significant SI difference on portal venous or transitional phases. HB phase SI changes in the TL compared to UL were significant at all TARE dose thresholds (p < 0.05).
CONCLUSIONS: SI differences between treated and untreated liver after TARE are most significant on the HB phase and present at all evaluated dose levels at a median of 6 months after treatment. These findings support the parenchymal ablative potential for TARE and the necessity to consider liver function loss within targeted liver volumes.
引用
- Syed M, Shah J, Montazeri SA, et al. Analysis of dynamic hepatobiliary contrast-enhanced MRI signal intensity after Yttrium-90 radioembolization with glass microspheres for the treatment of hepatocellular carcinoma. Abdom Radiol (NY). 2020. PMID: 33216180. doi:10.1007/s00261-020-02855-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。